5 unknown, 4 completed, 2 recruiting, 2 terminated. 13 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 13 | Unknown 5, Completed 4, Recruiting 2, Terminated 2 |
Follow Cobicistat: new trials by email Literature Review of Cobicistat trials Research Report on Cobicistat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up Dual therapy: darunavir/cobicistat + lamivudine, Triple therapy: darunavir/cobicistat plus tenofovir alafenamide/emtricitabine - HIV Infection, Antiretroviral Therapy | Phase 4 | Recruiting | Instituto Mexicano del Seguro Social | 78 | 2025-07-10 | 2026-07-01 |
| Effect of Dolutegravir Compared With Darunavir/Cobicistat on the Severity of Neuropsychiatric Effects al 12 Weeks in Antirretroviral Treatment-Naive Adults. Dolutegravir (DTG), Darunavir/Cobicistat (FDC) - HIV, Insomnia | Phase 4 | Unknown | Instituto Mexicano del Seguro Social | 140 | 2025-06-19 | 2025-06-26 |
| A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments F/TAF (High Dose Tablet), F/TAF (Low Dose Tablet), F/TAF (Lowest Dose Tablet) - HIV-1-infection | Phase 4 | Recruiting | Gilead Sciences | 350 | 2024-08-27 | 2026-10-19 |
| Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat Cobicistat - Non-small Cell Lung Cancer | Phase 4 | Unknown | Maastricht University Medical Center | 60 | 2024-04-01 | 2024-08-09 |
| Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness Olaparib, Cobicistat - Cancer | Phase 4 | Unknown | Radboud University Medical Center | 160 | 2021-12-15 | 2024-06-12 |
| Contribution of Dolutegravir to Obesity and Cardiovascular Disease Dolutegravir 50 MG, Antiretroviral/Anti HIV - HIV-1-infection, Antiviral Drug Adverse Reaction | Phase 4 | Completed | Augusta University | 10 | 2020-09-17 | 2023-07-27 |
| Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study Experimental: RAL QD, Active comparator: DRV/cb - HIV Infections | Phase 4 | Unknown | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | 75 | 2019-04-01 | 2019-02-15 |
| EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS Dolutegravir (DTG) plus Darunavir/cobicistat (DRV/cobi)., Current ART - HIV-1 Infection | Phase 4 | Completed | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 96 | 2018-11-19 | 2022-04-01 |
| Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X) emtricitabine, darunavir/cobicistat, maraviroc - Hiv, Neurocognitive Dysfunction | Phase 4 | Terminated | Giovanni Di Perri | 38 | 2017-05-15 | 2020-11-06 |
| RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection Rilpivirine + darunavir/cobicistat - HIV Infection | Phase 4 | Unknown | A.O. Ospedale Papa Giovanni XXIII | 1609 | 2017-02-01 | 2019-08-22 |
| Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals Darunavir, ritonavir, cobicistat - AIDS-related Dementia Complex | Phase 4 | Terminated | University Hospital, Basel, Switzerland | 7 | 2015-07-01 | 2017-02-02 |
| Renal Integrase Study Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat), Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet, Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir) - HIV | Phase 4 | Completed | St Stephens Aids Trust | 60 | 2015-03-01 | 2017-06-27 |
| An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks - HIV-2 Infection | Phase 4 | Completed | University of Washington | 30 | 2014-09-01 | 2018-07-26 |
HIV Infections (3) · AIDS Dementia Complex (1) · Acquired Immunodeficiency Syndrome (1) · Anxiety Disorders (1) · Body Weight Changes (1) · Carcinoma, Non-Small-Cell Lung (1) · Cardiovascular Abnormalities (1) · Cognition Disorders (1) · Depression (1) · HIV-Associated Lipodystrophy Syndrome (1) · Lentivirus Infections (1) · Neoplasms (1) · Sleep Initiation and Maintenance Disorders (1) · Suicide (1) · Vascular Diseases (1)
Instituto Mexicano del Seguro Social (2) · A.O. Ospedale Papa Giovanni XXIII (1) · Augusta University (1) · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (1) · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (1) · Gilead Sciences (1) · Giovanni Di Perri (1) · Maastricht University Medical Center (1) · Radboud University Medical Center (1) · St Stephens Aids Trust (1) · University Hospital, Basel, Switzerland (1) · University of Washington (1)
Italy (2) · Netherlands (2) · Argentina (1) · Mexico (1) · Panama (1) · Senegal (1) · South Africa (1) · Spain (1) · Switzerland (1) · Thailand (1) · Uganda (1) · United Kingdom (1) · United States (1) · Zimbabwe (1)
Geoffrey S Gottlieb, MD PhD (1) · Graeme Moyle, MD, MBBS, Dip GUN (1) · Jonell B Poe, MPAS (1) · Lizza Hendriks, MD, PhD (1) · Manuel Battegay (1) · Moussa Seydi, MD (1) · Nielka van Erp, prof. PharmD PhD (1)
PMID 11813503, PMID 11915000, PMID 19532059, PMID 23824675, PMID 27629070, PMID 28575323, PMID 29672676, PMID 32129855, PMID 35079789, PMID 35324881, PMID 35485333, PMID 36309038, PMID 37806255, PMID 37906406, PMID 38023553, PMID 38091533, PMID 39116868, PMID 39570084, PMID 39909979, PMID 40248173
2023 (1)